New
Off-Market — Email and mobile phone retrieval is now available.

off-market / proprietary sourcing

The best targets are not on the market.

Off-Market presents companies that never appear on investment bankers' lists.

~90%

of companies are private

5-criterion

transparent fit score

Multi-model

sourced & verified

off-market / live sourcing SCORING
thesis interventional medtech · US · founder-led · >+10% growth
MV
Meridian Vascular US · private · 38 FTE
94FIT
CV
Corveo Diagnostics US · private · 51 FTE
91FIT
HA
Halden Medtech US · private · 44 FTE
88FIT
AS
Aumont Surgical US · private · 29 FTE
85FIT
34 more matched · not publicly for sale updated 2 min ago
01

Defining research in seven steps

You outline the criteria for the target company—its business activities, location, and size—and Tittan turns this brief into an active search.

Each step is validated as the process unfolds; no operations are launched until the search is finalized.

🔒 app.tittan.io / projects / new
SETUP
STEP 1 OF 7 1 / 7

02

off-market / source & score

Every match, scored and explained.

Once the search is launched, Tittan generates a list of target companies and assigns a score to each one based on your five criteria.

Each score is accompanied by a justification, and the exact cost of the operation (in terms of tokens consumed) is clearly indicated.

Off-Market scoring results dashboard
03

off-market / scoring detail

Understand the scoring mechanism for each target.

Identify the various criteria for evaluating the target — each qualification is broken down, sourced and justified, so the reasoning behind a score is fully transparent.

TARGET DETAIL
Dexcom
Medical devices · Continuous glucose monitoring · San Diego, CA
Match
Tier 1 · matching target
5 / 5 criteria aligned

FIRMOGRAPHICS

🔖 VIA LINKEDIN
◎ Country
United States
HQ · California
☰ Headcount
10,001+
size band
👤 Members
11,100
associated

QUALIFICATION

✓ 5 / 5 aligned
CRITERION SPECIFICATION CLIENT REQUEST QUALIFICATION
Q1 Activity sought Company specialized in continuous glucose monitoring (CGM) medical devices for diabetes management. ✓ Yes
Q2 Applications Real-time glucose monitoring, type 1 and type 2 diabetes management, and metabolic health. ✓ Yes
Q3 Keywords
CGMContinuous glucoseDiabetes BiosensorMedical deviceDigital health Glucose sensorMetabolic healthMedTech
✓ Yes
Q4 Reference URL dexcom.com ✓ Yes
Q5 Activity to exclude ⚠ EXCLUSION CRITERION Pharmaceutical production — manufacturing of drugs or insulin. ✓ No Excluded activity
absent ·
favorable
READING  Inclusion criteria (Q1–Q4) validate the match when satisfied; the exclusion criterion (Q5) is favorable when the excluded activity is not detected.

JUSTIFICATION

Dexcom is a leading player in continuous glucose monitoring (CGM) medical devices, with a range of biosensors (G7, ONE+, Stelo) for diabetes management and metabolic health tracking. The company, listed on NASDAQ (DXCM) and operating internationally, directly matches the criteria sought. Nothing suggests an activity to exclude: pharmaceutical production is outside its scope.
Tittan — M&A deal intelligence
Firmographics via LinkedIn · Enriched Jul 2026
04

off-market / company sheet

All company information on a single sheet.

Buyer, target, country, workforce, source and next actions — every deal is consolidated on one line so you can scan, filter and drill in without hopping across tools.

Off-Market deals table with buyer, target, country, workforce, source and actions
05

Decide together, on the company card.

A target is a team decision. On each company's card your analysts and partners weigh in — request an opinion, drop a note, or record accept and reject — so the reasoning behind every shortlist lives with the company, not in an inbox.

🔒 app.tittan.io / targets / inari-medical
DEAL ROOM
💬 DISCUSSION ON THIS TARGET 3 in room
Shared with YK L M TK your team
◇ Opinion requested from 2 members
LM Léa MoreauANALYST ✓ Strong match
TK Thomas KleinPARTNER Pending
LM
Léa MoreauANALYST2h
Inari fits the interventional thesis cleanly — VTE focus, US-made, strong growth. Scored 5/5. @Yann worth a closer look for the comps set?
YK
You1h
Agree. It's public though, so let's tag it as a comparable rather than a direct target. @Thomas your read?
TK
Thomas KleinPARTNER24m
Good as a benchmark. Accept into the comparables shortlist, and let's move a private name like Meridian Vascular up for outreach.
✓ Accept Inari → comparables Léa · done
Accepted into shortlist · comparables
by Yann K. · today 14:32 · recorded on the card
Reply, or @mention a teammate…